A new lease of life for Pfizer's former biologics manufacturing facility in Adelaide.
BioCina acquired the facility from Pfizer and it has now been launched as a biologics contract development and manufacturing facility.
The facility offers full clinical supply services to biopharmaceutical companies. It specialises in process development and cGMP manufacturing for clinical trials and commercial use.
BioCina said it has expanded the facility's current capabilities and services to include the manufacture of mRNA vaccine drug substance and will be adding encapsulation using lipid nanoparticles in the second half of 2022.
“We have been working hard to make sure that we hit the ground running after transitioning this facility and operations from Pfizer,” said BioCina CEO Ian Wisenberg.
“The team has been working flat out to ensure that we stand up all the systems and comply with all the regulatory requirements to be fully operational.
“Our mission is to combine world class science with efficient delivery of high-quality, cost-effective microbial process development and manufacturing solutions, enabling our customers to deliver therapies on time to the patients who need them.
“This is at the core of the BioCina team’s capability, experience and passion.
"BioCina is making a significant investment in and strategically focusing on mRNA process development and manufacturing for vaccines and therapeutics to support solutions using this mRNA platform for our clients."